These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 35478222)

  • 1. Anti-tuberculosis treatment strategies and drug development: challenges and priorities.
    Dartois VA; Rubin EJ
    Nat Rev Microbiol; 2022 Nov; 20(11):685-701. PubMed ID: 35478222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tuberculosis--advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers.
    Wallis RS; Maeurer M; Mwaba P; Chakaya J; Rustomjee R; Migliori GB; Marais B; Schito M; Churchyard G; Swaminathan S; Hoelscher M; Zumla A
    Lancet Infect Dis; 2016 Apr; 16(4):e34-46. PubMed ID: 27036358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategies to Combat Multi-Drug Resistance in Tuberculosis.
    Singh V; Chibale K
    Acc Chem Res; 2021 May; 54(10):2361-2376. PubMed ID: 33886255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Harnessing Biological Insight to Accelerate Tuberculosis Drug Discovery.
    de Wet TJ; Warner DF; Mizrahi V
    Acc Chem Res; 2019 Aug; 52(8):2340-2348. PubMed ID: 31361123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving the tuberculosis drug development pipeline.
    Evangelopoulos D; McHugh TD
    Chem Biol Drug Des; 2015 Nov; 86(5):951-60. PubMed ID: 25772393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New perspectives on the treatment of mycobacterial infections using antibiotics.
    He Y; Fan A; Han M; Zhang Y; Tong Y; Zheng G; Zhu S
    Appl Microbiol Biotechnol; 2020 May; 104(10):4197-4209. PubMed ID: 32185432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tuberculosis clinical trial update and the current anti-tuberculosis drug portfolio.
    Palomino JC; Martin A
    Curr Med Chem; 2013; 20(30):3785-96. PubMed ID: 23862617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers of treatment response in clinical trials of novel antituberculosis agents.
    Perrin FM; Lipman MC; McHugh TD; Gillespie SH
    Lancet Infect Dis; 2007 Jul; 7(7):481-90. PubMed ID: 17524807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs.
    Clemens DL; Lee BY; Silva A; Dillon BJ; Masleša-Galić S; Nava S; Ding X; Ho CM; Horwitz MA
    PLoS One; 2019; 14(5):e0215607. PubMed ID: 31075149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarkers for TB treatment response: challenges and future strategies.
    Walzl G; Ronacher K; Djoba Siawaya JF; Dockrell HM
    J Infect; 2008 Aug; 57(2):103-9. PubMed ID: 18649943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advancements in the development of anti-tuberculosis drugs.
    Chetty S; Ramesh M; Singh-Pillay A; Soliman ME
    Bioorg Med Chem Lett; 2017 Feb; 27(3):370-386. PubMed ID: 28017531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges in the clinical assessment of novel tuberculosis drugs.
    Dooley KE; Phillips PP; Nahid P; Hoelscher M
    Adv Drug Deliv Rev; 2016 Jul; 102():116-22. PubMed ID: 26827911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pipeline of drugs for related diseases: tuberculosis.
    Dooley KE; Nuermberger EL; Diacon AH
    Curr Opin HIV AIDS; 2013 Nov; 8(6):579-85. PubMed ID: 24100880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Recent progress in mycobacteriology].
    Okada M; Kobayashi K
    Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advancing the development of tuberculosis therapy.
    Zumla A; Hafner R; Lienhardt C; Hoelscher M; Nunn A
    Nat Rev Drug Discov; 2012 Mar; 11(3):171-2. PubMed ID: 22378254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The quest for the holy grail: new antitubercular chemical entities, targets and strategies.
    Huszár S; Chibale K; Singh V
    Drug Discov Today; 2020 Apr; 25(4):772-780. PubMed ID: 32062007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The future for early-stage tuberculosis drug discovery.
    Zuniga ES; Early J; Parish T
    Future Microbiol; 2015; 10(2):217-29. PubMed ID: 25689534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges and opportunities in developing novel drugs for TB.
    Kaneko T; Cooper C; Mdluli K
    Future Med Chem; 2011 Sep; 3(11):1373-400. PubMed ID: 21879843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current Advances in Antitubercular Drug Discovery: Potent Prototypes and New Targets.
    Dos Santos Fernandes GF; Jornada DH; de Souza PC; Chin CM; Pavan FR; Dos Santos JL
    Curr Med Chem; 2015; 22(27):3133-61. PubMed ID: 26282941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.